Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
256840.KQ
STRONG SELLBNC KOREA, Inc. · Healthcare · South Korea · $131M · Avg Vol: $955K/d
19
StockRankQ
52
V
42
M
15
P/E (TTM)
67.3x
ROE
-1.8%
D/E
0.1x
Dividend %
2.5%
COMPANY DESCRIPTION
BNC KOREA, Inc. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 28M | 53M | 59M | 63M | 31.4% |
| EPS | -0.47 | 0.26 | 0.13 | 0.03 | -67.1% |
| Shares | 68M | 68M | 68M | 68M | +1.2% |
| Debt | 9M | 1M | 10M | 17M | 24.4% |
| Equity | 121M | 138M | 151M | 154M | 8.3% |
| Op CF | -4M | 11M | 11M | 5M | -34.0% |
| Inv CF | -24M | -29M | -8M | -6M | — |
| Fin CF | 81M | -12M | 10M | 7M | — |
Loading...
PRICE (1M)-27.1%
SMA 50SMA 200
Close
$1.87
RSI (14)
35.1
52W High
$4.00
From 52W High
0.5%
SCORE BREAKDOWN
Quality
52
ROIC
1.9%48.2
ROE
-1.8%42.6
GP/Assets
12.4%30.5
Op. Margin
-7.1%30.9
FCF/Assets
1.6%56.4
Piotroski
—83.4
Int. Cover
7.9x61.1
D/E Ratio
0.11x64.3
Current Ratio
5.10x71.3
Value
42
P/E (TTM)
67.3x14.2
EV/EBITDA
15.0x27.8
P/FCF
66218.1x25.2
P/B
0.8x83.4
P/S
2.2x65.6
Div Yield
2.5%60.1
Momentum
15
52W High %
47%20.0
RS 6M
-168%1.1
SMA 50/200
0.78x11.3
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$131M
P/E (Forward)
—
Gross Margin
37.9%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 256840.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 256840.KQ | BNC KOREA, Inc.(you) | $131M | 19 | STRONG SELL |
| 004310.KS | Hyundai Pharmaceutical Co., Ltd. | $117M | 23 | SELL |
| 058820.KQ | CMG Pharmaceutical Co., Ltd. | $107M | 14 | STRONG SELL |
| 000520.KS | Samil Pharmaceutical Co.,Ltd | $105M | 14 | STRONG SELL |
| 003520.KS | Yungjin Pharm. Co., Ltd. | $158M | 10 | STRONG SELL |
| 067080.KQ | DAE HWA Pharmaceutical Co., Ltd. | $127M | 7 | STRONG SELL |
| 002390.KS | HANDOK Inc. | $73M | 17 | STRONG SELL |
| 214390.KS | Kyongbo Pharmaceutical Co., Ltd | $91M | 27 | SELL |
| 183490.KQ | Enzychem Lifesciences Corporation | $55M | 18 | STRONG SELL |
| 003220.KS | Daewon Pharmaceutical Co., Ltd. | $124M | 37 | HOLD |
Peer medians: ROE -1.1% · P/E 17.6x · Gross margin 43.6%